| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Soligenix Inc. | Pentoxifylline | Behçet's Disease (BD) | Phase 2/3 | Trial Planned | Oral | Immunology |
| Soligenix Inc. | HyBryte (synthetic hypericin) - (RW-HPN-MF-01) | Early-stage cutaneous T-cell lymphoma (CTCL) | Phase 2 | Data Released | Topical | Oncology |
| Soligenix Inc. | SGX302/hypericin sodium | Psoriasis | Phase 2a | Data Released | Topical | Immunology |
| Sonnet BioTherapeutics Holdings Inc. | SON-080 | Diabetic Peripheral Neuropathy (DPN) | Phase 2a | Ongoing | Subcutaneous | Neurology |
| Sorrento Therapeutics Inc. | SEMDEXA (SP-102) - (CLEAR) | Lumbosacral radicular pain (sciatica) | Phase 3 | Epidural injection | Neurology | |
| Sorrento Therapeutics Inc. | ABIVERTINIB (STI-5656) | Non-small cell lung cancer (NSCLC) | Phase 3 | Oral | Oncology | |
| Sorrento Therapeutics Inc. | Abivertinib | COVID-19 | Phase 2/3 | Oral | COVID-19 | |
| Sorrento Therapeutics Inc. | SP-103 | Acute lower back pain (LBP) | Phase 2 | Transdermal | Orthopedic |